Atlas Trials

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy

Clinical trial NCT05104775 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05104775
Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Hematologic Malignancies
Start date
2022-02-09
Primary completion
2025-12-01
Enrollment
33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.